### **Overview of Philips' Business Divisions and 2024 Financial Performance**

In 2024, Philips executed its three-year strategic plan, delivering improved profitability and strong cash flow despite a challenging macroeconomic environment, particularly with a significant decline in demand in China. The company's strategy is centered on creating value through focused growth, scalable patient- and people-centric innovation, and reliable execution. Philips' operations are structured into three main divisions: Diagnosis & Treatment, Connected Care, and Personal Health.

#### **Overall Group Financial Performance (2024)**

Philips demonstrated solid underlying growth and operational improvements. Group sales reached **EUR 18.0 billion**, a **1% increase** on a comparable basis. The company significantly improved profitability, with the **Adjusted EBITA margin increasing by 90 basis points to 11.5%**. Free cash flow was strong at **EUR 906 million**, bolstered by insurance proceeds related to the Respironics recall. However, the company reported a **net loss of EUR 698 million**, primarily due to a substantial litigation provision for the Respironics settlements. The company has proposed maintaining its dividend at **EUR 0.85 per share**.

*   **Productivity and Restructuring:** Philips completed its plan to reduce its global workforce by **10,000 roles** ahead of schedule and increased its productivity savings target for 2023-2025 from EUR 2 billion to **EUR 2.5 billion**.

---

### **Diagnosis & Treatment Division**

This division is Philips' largest by revenue, focusing on providing AI-enabled solutions that support precision diagnosis and minimally invasive treatments in areas like cardiology, oncology, and neurology.

*   **Financial Performance:**
    *   **Sales:** **EUR 8.79 billion**, representing a **1%** increase in comparable sales for the full year.
    *   **Adjusted EBITA Margin:** **11.6%**, remaining stable year-over-year.

*   **Revenue & Profit Drivers:**
    *   **Key Growth Segment:** Growth was driven by mid-single-digit performance in **Image-Guided Therapy**.
    *   **Declining Segment:** This growth was partially offset by a decline in **Precision Diagnosis**, mainly attributed to extended hospital procurement cycles and challenging market conditions in China.
    *   **Geographic Performance:** Mature geographies, led by North America, showed mid-single-digit growth, while growth geographies saw a low-single-digit decline due to China.

*   **Strategic Investments & Developments:**
    *   **Key Products & Innovations:**
        *   **Helium-Free MRI:** Continued rollout of the **BlueSeal MRI** technology, with over 1,500 systems now installed globally, promoting sustainable access to advanced imaging.
        *   **Computed Tomography (CT):** Received FDA clearance for the **Philips CT 5300**, which features AI-based reconstruction software to lower radiation doses, and the **Spectral CT 7500 RT** for personalized radiation therapy planning.
        *   **Image-Guided Therapy:** Launched the **Zenition 90 Motorized** system for complex vascular procedures and received FDA approval for the **LumiGuide Navigation Wire**, which uses fiber optics to reduce radiation exposure.
    *   **Strategic Collaborations:**
        *   Expanded its partnership with **Amazon Web Services (AWS)** to offer a cloud-based integrated diagnostics portfolio.
        *   Announced a collaboration with the **Mayo Clinic** to use AI to improve diagnostic MRI for heart disease.
        *   Partnered with **Carilion Clinicâ€™s Cardiovascular Institute** to deploy 11 specialized Philips interventional suites.

### **Connected Care Division**

This division connects patients and caregivers across different settings through patient monitoring, enterprise informatics, and solutions for sleep and respiratory conditions.

*   **Financial Performance:**
    *   **Sales:** **EUR 5.13 billion**, showing a **2%** increase in comparable sales for the full year.
    *   **Adjusted EBITA Margin:** Showed significant improvement, reaching **9.6%** compared to 7.2% in 2023.

*   **Revenue & Profit Drivers:**
    *   Growth was driven by strong performance in **Enterprise Informatics** and **Sleep & Respiratory Care**.
    *   This was partially offset by a decline in the **Monitoring** business, which was compared against a period of strong double-digit growth in the prior year.
    *   **Respironics Recall:** The division's performance was heavily influenced by the ongoing resolution of the Respironics recall. In 2024, Philips finalized the US medical monitoring and personal injury settlements, agreeing to pay a total of **USD 1.1 billion**. The company's free cash flow was positively impacted by **EUR 367 million** in related insurance proceeds.

*   **Strategic Investments & Developments:**
    *   **Divestment:** Announced an agreement to sell its **Emergency Care Business Unit** to Bridgefield Capital, a transaction expected to close in the second half of 2025.
    *   **AI and Cloud:** Expanded its collaboration with AWS to launch the **Tasy EMR AI Virtual Assistant** in Latin America.
    *   **Strategic Partnerships:** Entered a multi-year collaboration with **Bon Secours Mercy Health (BSMH)** focused on patient monitoring.

### **Personal Health Division**

As Philips' most profitable division by margin, this segment offers a range of consumer-focused products for healthy living, including oral healthcare, personal care, and mother and child care.

*   **Financial Performance:**
    *   **Sales:** **EUR 3.49 billion**, representing a **1%** decrease in comparable sales for the full year.
    *   **Adjusted EBITA Margin:** A very strong **16.7%**, up slightly from 16.6% in 2023.

*   **Revenue & Profit Drivers:**
    *   The sales decline was primarily due to a **double-digit decline in China** resulting from subdued consumer sentiment. This decline offset strong performance and growth in other geographies.
    *   The margin remained robust due to operational improvements and productivity measures.

*   **Strategic Investments & Developments:**
    *   **New Products:** Launched innovative products like **OneBlade Intimate**, the **AI-powered Avent Premium Connected Baby Monitor** with cry translation, and the **On-The-Go Compact Shaver** in China.
    *   **Sustainability:** Expanded the **Philips Refurb Editions** program in Europe, offering refurbished products with a full warranty to promote a circular economy.
    *   **Strategic Partnerships:** Partnered with **March of Dimes** in North America to support parents and improve access to care in underserved communities.

---

### **Special Focus: Digital Pathology and Genetic Sequencing**

#### **Digital Pathology**

Digital pathology is a key strategic area for Philips within its **Diagnosis & Treatment** division, aimed at transforming traditional pathology workflows into a digital, data-driven discipline. In 2024, Philips advanced this area through:

*   **Strategic Partnerships:** Launched a digital pathology program with **NYU Langone Health** in the US, designed to provide superior clarity in tissue sample analysis, enhance collaboration among pathologists, and significantly reduce diagnosis times.
*   **Foundation for AI:** This program is crucial for creating the infrastructure needed to deploy advanced **AI algorithms**, which will further enhance diagnostic accuracy and speed.
*   **Cloud Integration:** The expansion of the strategic collaboration with **Amazon Web Services (AWS)** includes making digital pathology solutions available on the cloud, improving access and unifying diagnostic workflows.
*   **Focus on Cancer Care:** As part of its long-standing relationship with the **US Veteran's Administration (VA)**, Philips is working to accelerate the adoption of digital pathology to speed up cancer diagnosis and care.

#### **Genetic Sequencing**

Based on a comprehensive review of the Philips Annual Report 2024 and the Q4 2024 results, **Philips has no significant business activities, products, or strategic initiatives related to genetic or genomic sequencing**. The company's core R&D and commercial activities are focused on diagnostic imaging, image-guided therapy, patient monitoring, health informatics, and personal health consumer products.
